Ella W.
- Country
- Austria
- Department
- Studienambulanz Hämatologie und Onkologie
Research Overview
- Phase 3 Randomized Study of Zanubrutinib vs. Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of Ibrutinib and Rituximab in Treatment-naïve Follicular Lymphoma Patients
- Phase 2 Multicenter Study of Rituximab, Polatuzumab Vedotin, and Glofitamab in Untreated Aggressive B-cell Lymphoma Patients Aged >60 Ineligible for R-CHOP
Data & Insights
Has run more than one trial at 40 of 257 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating various forms of lymphoma, with particular focus on aggressive B-cell lymphoma and follicular lymphoma. Their research encompasses innovative therapeutic approaches for both treatment-naïve and previously untreated patients.
- Advanced Hodgkin Lymphoma Management
- B-cell Lymphoma Treatment Strategies
- Follicular Lymphoma Interventions
Their expertise extends to evaluating novel treatment combinations and targeted therapies for lymphoma patients.
Leukemia Studies
The investigator conducts research in chronic lymphocytic leukemia and small lymphocytic lymphoma, focusing on comparative treatment efficacy and innovative therapeutic approaches.
- Novel Agent Evaluation
- Treatment Comparison Studies
- Progressive Disease Management
Their work involves assessing progression-free survival outcomes in various treatment modalities.
Therapeutic Innovation
The investigator explores chemotherapy-light combinations and evaluates novel therapeutic approaches including antibody-drug conjugates and bispecific antibodies.
- Combined Immunotherapy Approaches
- Targeted Treatment Strategies
- Toxicity Reduction Methods
Their research emphasizes developing treatment options for elderly patients and those unsuitable for conventional therapeutic regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.